Assay for anti-INGAP antibodies

a technology of antibodies and antibodies, applied in the field of antibodies, can solve the problems of limited regeneration capacity and limited regeneration capacity

Inactive Publication Date: 2007-08-09
VINIK AARON I +1
View PDF2 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, they have a limited capacity for regeneration.
This limited regeneration capacity predisposes mammals to develop diabetes mellitus.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Assay for anti-INGAP antibodies
  • Assay for anti-INGAP antibodies
  • Assay for anti-INGAP antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Specificity of Anti-INGAP104-118 Antibodies

[0034] To examine the specificity of the rabbit anti-INGAP104-118 antibody, rabbit anti-INGAP104-118 antibody was incubated in microtiter wells pre-coated with INGAP104-118, bovine serum albumin (BSA), INGAP151-164 (Cterm), or INGAP139-152 (Cseq). All peptide-coated wells had an equivalent concentration of peptide. Anti-INGAP104-118 antibody binding was assessed using an anti-rabbit IgG alkaline phosphatase (AP) conjugate detection antibody. Samples were incubated with pNPP and the optical density (OD) monitored at 405 nm. FIG. 2 demonstrates that rabbit anti-INGAP104-118 antibody binds specifically to INGAP104-118 since only wells containing anti-INGAP104-118 antibody exhibited a significant OD405 upon incubation with pNPP. It was concluded that this antibody specifically binds to INGAP104-118 peptide enabling its use in assay development.

Sensitivity of Anti-INGAP104-118 Antibodies

[0035] The sensitivity of rabbit anti-INGAP104-118 ant...

example 2

Immunoassay Protocol for Anti-INGAP104-118 in Human Serum

[0039] The reagents used in this example are as follows: TBS (0.05 M TRIS, 0.138 M NaCl, 0.0027 KCl, pH 8.0 at 25° C.), TBS-TW (TBS containing 0.05% Tween-20 (polyoxyethylene-borbitan monolaurate)), Blocking Solution for Matrix Dilution Buffer (TBS-TW containing 1% w / v bovine serum albumin), Secondary Antibody Detection for Human Sera (1:5000 dilution of anti-human IGg, AP conjugated (Sigma A-1543) in Blocking solution), Secondary Antibody Detection for Rabbit Antibody (1:5000 dilution of anti-rabbit IGg, AP conjugated (Sigma A-2556) in Blocking solution), Matrix Dilution Buffer (1:25 human serum:blocking solution, v / v), and pNPP Substrate Buffer (one set para-nitrophenyl phosphate tablets (Sigma N-1891) in 5 mL deionized water).

[0040] Rabbit anti-INGAP104-118 antibody was supplied by Strelitz Diabetes Institute.

[0041] Standard Curve—Standard curve was prepared according to the following table:

250 ng / mLMatrixCalibrationMa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
ODaaaaaaaaaa
Login to view more

Abstract

A solid phase assay is used for detecting antibodies to INGAP104-118 peptide, a 15-amino acid peptide that is the biologically active portion of islet neogenesis associated protein (INGAP). The isotype of the antibodies to INGAP104-118 peptide can be determined. A kit can also be used in the detection of anti-INGAP104-118 antibodies. Endogenous autoantibodies or antibody production during therapeutic treatment of a mammal with INGAP104-118 can be monitored.

Description

[0001] This application is a Divisional Application of parent application Ser. No. 10 / 376,046, filed on Feb. 27, 2003, which claims the benefit of provisional application Ser. No. 60 / 361,040 filed on Mar. 1, 2002.FIELD OF THE INVENTION [0002] The invention relates to the field of assays for antibodies. Specifically, the invention relates to antibodies raised in mammals against administered therapeutic agents. BACKGROUND OF THE INVENTION [0003] Pancreatic islets of Langerhans are the only organ of insulin production in the body. However, they have a limited capacity for regeneration. This limited regeneration capacity predisposes mammals to develop diabetes mellitus. Islet neogenesis associated protein (INGAP) plays a role in stimulation of islet neogenesis, in particular, in beta cell regeneration from ductal cells. INGAP104-118 peptide (IGLHDPSHGTLPNGS, SEQ ID NO: 1), a 15-amino acid peptide comprising amino acids 104-118 of the INGAP protein, is biologically active and is capable ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/53C07K14/47C07K16/18G01N33/537G01N33/543G01N33/68
CPCG01N33/6854G01N2410/00G01N2333/474G01N2333/4733G01N33/543G01N33/53
Inventor VINIK, AARON I.TAYLOR-FISHWICK, DAVID A.
Owner VINIK AARON I
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap